Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK117 + Azacitidine + Venetoclax in AML
NCT06387420Phase 2Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab in acute myeloid leukemia (AML), sponsored by Akeso, Inc.. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
ligufalimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06387420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387420.